FDA restarts domestic drug manufacturing inspections
After a pause of 41 days, the FDA restarted its domestic pharma-related surveillance inspections on Monday.
That decision to restart, which came as a result …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
